Hexoprenaline


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Relief of bronchoconstriction 0.5-1 mg 3 times/day. IV Premature labour As sulfate: Loading dose: 10 mcg, followed by 0.3 mcg/min. Inhalation Relief of bronchoconstriction As aerosol: As sulfate: 100-200 mcg up to 6 times/day. As nebulising soln: As HCl: 250-500 mcg 4-6 hrly. Max: 3 mg/day.
Dosage Details
Inhalation/Respiratory
Relief of bronchoconstriction
Adult: As sulfate: 100-200 mcg up to 6 times/day by aerosol inhalation. As HCl: 250-500 mcg every 4-6 hr by nebulisation; max: 3 mg/day for nebulisation.

Intravenous
Premature labour
Adult: As sulfate: slow IV Inj of 10 mcg loading dose over 5-10 minutes, followed by an initial infusion rate of 0.3 mcg/minute. Prolonged infusion at 0.075 mcg/minute may be given if there is no cervical change.

Oral
Relief of bronchoconstriction
Adult: 0.5-1 mg tid.
Administration
Should be taken on an empty stomach. Take 30 min before meals.
Contraindications
Heavy genital haemorrhage, premature separation of the placenta, intra-uterine infections, severe myocardial insufficiency.
Special Precautions
CV disorders including heart disease, severe hypertension and hypotension, hyperthyroidism, DM, patients who respond unusual to sympathomimetics. Thyrotoxicosis, tachycardiac arrhythmias, myocarditis, hypotension, severe renal disease, mitral valve defects, idiopathic hypertrophic subvalvular aortic stenosis. Risk of pulmonary oedema in patients being treated for premature labor. Pregnancy, lactation.
Adverse Reactions
Occasionally, tachycardia. Palpitation and skeletal muscle tremor (on high and cumulative doses).
Drug Interactions
MAOIs, TCAs, β-blockers, calcium- and vitamin D-containing preparations, dihydrotachysterol, mineralocorticoids, methylxanthines, glucocorticoids.
Action
Description: Hexoprenaline is a direct-acting sympathomimetic with predominantly β-adrenergic activity selective to β2-receptors.
Disclaimer: This information is independently developed by MIMS based on Hexoprenaline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in